EEG Analysis for Alzheimer's Identification: Frontiers Review

A new review published in Frontiers examines how EEG analysis can identify Alzheimer's disease, consolidating the field's evidence on whether routine electrophysiology can serve as a practical marker of neurodegeneration.

The review, titled "The EEG analysis and identification of Alzheimer's disease: a review," surveys analytical approaches applied to EEG recordings in Alzheimer's patients and assesses how far signal-based methods have progressed toward reliable identification of the disease.

Why Alzheimer's is an EEG story

Alzheimer's disease progressively disrupts the cortical networks that generate the scalp EEG. This makes electrophysiology an attractive candidate biomarker: it is non-invasive, inexpensive compared with PET imaging and CSF sampling, and already standard equipment in clinical neurophysiology labs. The review addresses the central question of whether EEG changes are specific and sensitive enough to support identification of Alzheimer's disease rather than merely describing its late-stage effects.

What the review covers

The authors survey the principal strands of EEG research in Alzheimer's disease:

• Quantitative EEG analysis of background rhythm changes associated with the disease
• Computational and machine-learning approaches aimed at classifying Alzheimer's patients from EEG recordings
• The comparative performance of different analytical techniques reported across the literature

By framing the work as a review, the authors consolidate findings that are otherwise scattered across individual studies using differing cohorts, montages and analytical pipelines — a long-standing obstacle to judging how well EEG-based identification generalizes across populations and recording conditions.

What this means for the reading room

For clinical neurophysiologists, the review's relevance is direct. Scalp EEG is routinely acquired in dementia workups, often to exclude epilepsy or transient confusional states. The question the review engages is whether the same recordings, analyzed quantitatively, could carry diagnostic weight for Alzheimer's itself rather than serving only as a rule-out tool.

The review's scope spans research-grade analysis rather than FDA-cleared diagnostic algorithms. No EEG-based classifier for Alzheimer's disease currently holds regulatory clearance as a standalone diagnostic, so the methods surveyed remain investigational — an important distinction for readers translating the literature into clinical expectations.

Standing questions

Key open issues the review context raises for the field:

• Which analytical methods hold up across independent cohorts rather than single-lab datasets
• How EEG findings relate to disease stage — early identification versus late-stage description
• Whether signal-based classification can complement, not replace, established biomarkers such as imaging and CSF measures

The Frontiers review contributes a consolidated reference point for neurophysiology labs and computational groups working toward EEG-based Alzheimer's identification. Its publication signals continued momentum behind electrophysiological biomarkers, and the coming years will show whether the analytical methods it surveys can clear the validation hurdles required for clinical deployment.